Literature DB >> 9851935

Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases.

H Matsubara1.   

Abstract

Since the discovery of nonpeptidic ligands, the receptors for angiotensin (Ang) II have been classified into 2 subtypes (Ang II type 1 receptor [AT1-R] and Ang II type 2 receptor [AT2-R]). AT1-R mediates most of the cardiovascular actions of Ang II. AT2-R is expressed at very high levels in the developing fetus. Its expression is very low in the cardiovascular system of the adult. The expression of AT2-R can be modulated by pathological states associated with tissue remodeling or inflammation. In failing hearts or neointima formation after vascular injury, AT2-R is reexpressed in cells proliferating in interstitial regions or neointima and exerts an inhibitory effect on Ang II-induced mitogen signals or synthesis of extracellular matrix proteins, resulting in attenuation of the tissue remodeling. An extreme form of cell growth inhibition ends in programmed cell death, and this process, which is initiated by the withdrawal of growth factors, is also enhanced by AT2-R. Cardiac myocyte- or vascular smooth muscle-specific mice that overexpress AT2-R display an inhibition of Ang II-induced chronotropic or pressor actions, suggesting the role of AT2-R on the activity of cardiac pacemaker cells and the maintenance of vascular resistance. AT2-R also activates the kinin/nitric oxide/cGMP system in the cardiovascular and renal systems, resulting in AT2-R-mediated cardioprotection, vasodilation, and pressure natriuresis. These effects, transmitted by AT2-R, are mainly exerted by stimulation of protein tyrosine or serine/threonine phosphatases in a Gi protein-dependent manner. The expression level of AT2-R is much higher in human hearts than in rodent hearts, and the AT2-R-mediated actions are likely enhanced, especially by clinical application of AT1-R antagonists. Thus, in this review, the regulation of AT2-R expression, its cellular localization, its pathological role in cardiovascular and kidney diseases, and pharmacotherapeutic effects of AT2-R stimulation are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851935     DOI: 10.1161/01.res.83.12.1182

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  86 in total

1.  Vasoconstriction is determined by interstitial rather than circulating angiotensin II.

Authors:  Martin P Schuijt; René de Vries; Pramod R Saxena; Maarten A D H Schalekamp; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload.

Authors:  T Senbonmatsu; S Ichihara; E Price; F A Gaffney; T Inagami
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 3.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

4.  Role of the angiotensin II receptor blocker valsartan in heart failure.

Authors:  R L Webb; M de Gasparo
Journal:  Exp Clin Cardiol       Date:  2001

5.  Role of angiotensin II receptor subtypes in porcine basilar artery: functional, radioligand binding, and cell culture studies.

Authors:  Atsushi Miyamoto; Ryoko Wada; Aya Inoue; Shigeru Ishiguro; James K Liao; Akira Nishio
Journal:  Life Sci       Date:  2005-10-11       Impact factor: 5.037

6.  Angiotensin II Type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFα production.

Authors:  Peter M Abadir; Jeremy D Walston; Robert M Carey; Helmy M Siragy
Journal:  J Interferon Cytokine Res       Date:  2011-02-02       Impact factor: 2.607

7.  Foetal hypoxia increases cardiac AT(2)R expression and subsequent vulnerability to adult ischaemic injury.

Authors:  Qin Xue; Chiranjib Dasgupta; Man Chen; Lubo Zhang
Journal:  Cardiovasc Res       Date:  2010-09-23       Impact factor: 10.787

Review 8.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 9.  Are angiotensin receptor blockers neuroprotective?

Authors:  Christa Thöne-Reineke; Mathias Zimmermann; Christian Neumann; Maxim Krikov; Jun Li; Nadja Gerova; Thomas Unger
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

10.  Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.

Authors:  Yau-Sheng Tsai; Hyo-Jeong Kim; Nobuyuki Takahashi; Hyung-Suk Kim; John R Hagaman; Jason K Kim; Nobuyo Maeda
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.